•
Mar 31, 2020
Jaguar Health Q1 2020 Earnings Report
Jaguar Health reported consolidated financial results for the first quarter of 2020.
Key Takeaways
Jaguar Health's Mytesi net sales were approximately $0.8 million, and Mytesi gross (non-GAAP) sales were approximately $1.3 million, a decrease of 45% and 39%, respectively, over the first quarter of 2019. Total Mytesi prescription volume increased 16% compared to Q1 2019. The net loss was $7.9 million, compared to a net loss of $8.3 million in the first quarter of 2019.
Mytesi net sales were approximately $0.8 million.
Mytesi gross sales were approximately $1.3 million.
Total Mytesi prescription volume increased 16% year-over-year.
Net loss was $7.9 million.
Jaguar Health
Jaguar Health
Forward Guidance
There is a belief that Jaguar will host an investor call on Friday, May 15, 2020 at 8:30 a.m. Eastern Time.